Antonio Llombart-Cussac, Leonor Fernandez-Murga, Eduardo Martinez, Ana Santaballa, Begoña Bermejo, Alvaro Rodriguez-Lescure, Vega Iranzo, Pilar de la Morena, Jorge Iranzo-Barreira, Javier Cortés, Francois Riva, José Manuel Pérez García, Derek Dustin, Jose Vidal-Martinez, Sara Marín Liébana, Lucia Serrano-Garcia, Juan Miguel Cejalvo. "Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.1052